Daihan Pharmaceutical Co.,Ltd.

KOSDAQ:A023910 Voorraadrapport

Marktkapitalisatie: ₩152.9b

Daihan PharmaceuticalLtd Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Sungyoung Lee

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO1.6yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuurgeen gegevens

Recente managementupdates

Recent updates

Here's Why Daihan PharmaceuticalLtd (KOSDAQ:023910) Can Manage Its Debt Responsibly

Mar 02
Here's Why Daihan PharmaceuticalLtd (KOSDAQ:023910) Can Manage Its Debt Responsibly

Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Feb 09
Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Can You Imagine How Daihan PharmaceuticalLtd's (KOSDAQ:023910) Shareholders Feel About The 34% Share Price Increase?

Jan 19
Can You Imagine How Daihan PharmaceuticalLtd's (KOSDAQ:023910) Shareholders Feel About The 34% Share Price Increase?

What Kind Of Shareholders Hold The Majority In Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Shares?

Dec 18
What Kind Of Shareholders Hold The Majority In Daihan Pharmaceutical Co.,Ltd.'s (KOSDAQ:023910) Shares?

Does Daihan PharmaceuticalLtd (KOSDAQ:023910) Have A Healthy Balance Sheet?

Nov 27
Does Daihan PharmaceuticalLtd (KOSDAQ:023910) Have A Healthy Balance Sheet?

CEO

Sungyoung Lee (61 yo)

1.6yrs

Tenure

Sungyoung Lee is Chief Executive Officer of Daihan Pharmaceutical Co.,Ltd. from April 2023.